A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
The goal of this clinical research study is to learn if adding eflornithine to lomustine can help to control anaplastic astrocytoma (AA) better than treatment with lomustine alone. The safety of the drug combinations will also be studied.
Disease Group: Malignant neoplasms of eye brain and other parts of central nervous system
Treatment Agent: CCNU,Eflornithine
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Orbus Therapeutics, Inc.
IRB Review and Approval Date: 12/12/2016
Recruitment Status: Open
Projected Accrual: 280
Information and next steps
Malignant neoplasms of eye brain and other parts of central nervous system
For general questions about clinical trials: